ColoSeq Tumor Single Gene
General Information
- Lab Name
- ColoSeq Tumor Single Gene
- Lab Code
- CSQTS
- Epic Ordering
-
Order using "UW Genetics and Solid Tumor Test Request"
Place a separate order to draw the paired blood sample.
See tip sheet for more information (internal link).
- Description
ColoSeq™ Tumor Single Gene is designed to detect somatic mutations in a single gene of ColoSeq™ Panel. Somatic mismatch repair (MMR) mutations have been reported in colon and endometrial cancers which have IHC loss of MMR protein(s) and normal (negative) germline MMR testing.
ColoSeq™ Tumor is an option for patients who have had abnormal MMR IHC and normal germline testing, such as ColoSeq™. ColoSeq™ Tumor Single Gene is a multiplexed assay for tumor samples that detect mutations in single gene selected by ordering provider. Next-generation sequencing is performed on an Illumina instrument to detect single nucleotide variants, insertions, deletions, gene amplifications, and selected translocations.
NOTE: If germline MMR testing was performed in a different laboratory, a peripheral blood sample should be submitted in addition to tumor tissue.
For information on the full ColoSeq™ Tumor Panel, see ColoSeq Tumor Panel [CSQTP]
For information on germline ColoSeq™ Lynch and Polyposis Panel (comprehensive colon cancer risk panel) see, ColoSeq - Lynch and Polyposis Panel [COSEQ]
ColoSeq™ Panel Genes
Gene
RefSeq
Disease Association or Cancer Risk
Complete Sequencing
Del/Dup
Added
AKT1
NM_005163.2
Cowden-like, Breast, thyroid cancers, macrocephaly
Yes
Yes
October 2013
APC
NM_000038.5
FAP, Turcot
Yes
Yes
November 2011
AXIN2
NM_004655.3
Colon cancer, oligodontia
Yes
Yes
February 2015
BMPR1A
NM_004329.2
Juvenile Polyposis
Yes
Yes
January 2013
CDH1
NM_004360.3
Hereditary diffuse gastric cancer
Yes
Yes
June 2012
CHEK2
NM_007194.3
Li-Fraumeni-like
Yes
Yes
February 2015
CTNNA1
NM_0011903.2
Hereditary diffuse gastric cancer
Yes
Yes
October 2014
CTNNB1
NM_001904.3
Desmoid tumors
Yes
Yes
February 2023
EPCAM
NM_002354.2
Lynch
Yes
Yes
November 2011
GALNT12
NM_024642.4
Colon cancer
Yes
Yes
October 2013
MLH1
NM_000249.3
Lynch, Muir-Torre
Yes
Yes
November 2011
MLH3
NM_001040108.1
Mismatch repair deficiency
Yes
Yes
June 2020
MSH2, includes exon 1-7 inversion
NM_000251.1
Lynch, Muir-Torre
Yes
Yes
November 2011
MSH6
NM_000179.2
Lynch
Yes
Yes
November 2011
MUTYH
NM_001128425.1
MUTYH-associated polyposis
Yes
Yes
November 2011
NTHL1
NM_002528.5
Colon polyposis (recessive)
Yes
Yes
July 2016
PDGFRA
NM_006206
GIST
Yes
Yes
July 2016
PIK3CA
NM_006218.2
Cowden-like, Breast, thyroid cancer, macrocephaly
Yes
Yes
October 2013
PMS2
NM_000535.5
Lynch
Yes
Yes
November 2011
POLD1
NM_002691.3
Colon cancer
Yes
Yes
October 2013
POLE
NM_006231.2
Colon cancer
Yes
Yes
October 2013
PTEN
NM_000314.4
Cowden
Yes
Yes
June 2012
RPS20
NM_001023.3
Colon cancer
Yes
Yes
February 2015
SMAD4
NM_005359.5
Juvenile Polyposis
Yes
Yes
January 2013
TP53
NM_000546.5
Li-Fraumeni
Yes
Yes
June 2012
Single Gene Testing available for any gene on ColoSeq™
For information on single gene testing see BROCA/ColoSeq - Single Gene Analysis [SGN]
Known Mutation Testing
Known mutation testing is available for mutations identified at UW Laboratory Medicine. For information on single site testing of a known mutation in one of the genes listed above see BROCA/ColoSeq™ - Known Mutation Testing [KMU]
For information about how University of Washington Department of Laboratory Medicine reports variants, see Variant Classification and Clinical Reporting of Results.
For previous versions of ColoSeq™ - Lynch and Polyposis Panel, see Previous Versions, COSEQ.
- References
- Pritchard CC, et al. ColoSeq provides comprehensive lynch and polyposis syndrome mutational analysis using massively parallel sequencing. J Mol Diagn 2012, 14:357-66. 22658618
- Walsh T, et al. Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing. Proc Natl Acad Sci U S A 2010, 107:12629-33. 20616022
- Nord AS, Lee M, King MC, and Walsh T. Accurate and exact CNV identification from targeted high-throughput sequence data. BMC Genomics 2011, 12:184. 21486468
- Metzker ML. Sequencing technologies - the next generation. Nat Rev Genet 2010, 11:31-46. 19997069
- Rhees J, Arnold M, and Boland CR. Inversion of exons 1-7 of the MSH2 gene is a frequent cause of unexplained Lynch syndrome in one local population. Fam Cancer 2014, 13:219-25. 24114314
- Mensenkamp AR, et al. Somatic mutations in MLH1 and MSH2 are a frequent cause of mismatch-repair deficiency in Lynch syndrome-like tumors. Gastroenterology 2014, 146:643-646.e8. 24333619
- Haraldsdottir S, et al. Colon and endometrial cancers with mismatch repair deficiency can arise from somatic, rather than germline, mutations. Gastroenterology 2014, 147:1308-1316.e1. 25194673
- Salipante SJ, Scroggins SM, Hampel HL, Turner EH, and Pritchard CC. Microsatellite instability detection by next generation sequencing. Clin Chem 2014, 60:1192-9. 24987110
- Synonyms
- biallelic somatic, ColoSeq™, COSEQ, double somatic, EPCAM, hereditary nonpolyposis colorectal cancer, HNPCC, Lynch syndrome, MLH1, MSH2, MSH6, MSI, PMS2, UW-Oncoplex™
- Components
-
Code Name CTSGS ColoSeq Tumor Gene Analyzed CTSRE ColoSeq Tumor Result CTSIN ColoSeq Tumor Interpretation CTSCH ColoSeq Tumor Clinical History CTSMT ColoSeq Tumor Method CTSDI ColoSeq Tumor Director
Interpretation
- Method
Next-generation sequencing.
This assay sequences all exons, non repeating intronic sequences and select promoter regions of AKT1, APC, AXIN2, BMPR1A, CDH1, CHEK2, CTNNA1, CTNNB1, EPCAM, GALNT12, MLH1, MLH3, MSH2, MSH6, MUTYH, NTHL1, PDGFRA, PIK3CA, PMS2, POLE, POLD1, PTEN, RPS20, SMAD4, and TP53. Sequences are aligned to the human genome reference (hg19). Test performed by targeted capture for listed genes followed by next-generation sequencing with Illumina technology. This test was developed and its performance characteristics determined by the University of Washington Department of Laboratory Medicine. It has not been cleared or approved by the US Food and Drug Administration. This laboratory is certified under the Clinical Laboratory Improvement Amendments (CLIA) as qualified to perform high complexity clinical laboratory testing. This test is used for clinical purposes. It should not be regarded as investigational or for research.
- Reference Range
- See individual components
- Ref. Range Notes
No mutations detected
- Guidelines
Ordering & Collection
- Specimen Type
- Formalin-Fixed Paraffin Embedded Tumor Tissue (FFPE), Purified DNA, Peripheral Blood, cultured cells from skin biopsy, purified DNA from peripheral blood or cultured cells, saliva
- Collection
-
Tumor specimen will be requested directly, by UW Laboratory Medicine, from the originating pathology department. In order to facilitate this, a pathology report should be submitted with the test requisition, blood control and other clinical and billing paperwork. NOTE: This test requires BOTH tumor tissue and peripheral blood. Only tumor tissue is required if ColoSeq™ testing on peripheral blood has been done previously at UW Lab Medicine.
Tumor Tissue:
Tumor specimen will be requested directly, by UW Laboratory Medicine, from the originating pathology department. In order to facilitate this, a pathology report should be submitted with the test requisition, blood control and other clinical and billing paperwork.
If the tumor specimen is being submitted by the ordering provider, tissue samples (FFPE) either (a) slides, OR (b) tissue block are required.
(a) Instructions for slide specimens: 1 slide at 4-micron thickness stained with hematoxylin-and-eosin AND 20 unstained, non-baked slides at 10-micron thickness (a minimum of 10 unstained slides is acceptable). Unstained slides can be on charged or uncharged slides. Note: Sections should contain as much tumor tissue as possible.
(b) Instructions for tissue block specimen: Provide complete tissue block containing tumor tissue. If there is more than one tissue block, please provide the block that has the greatest amount of tumor tissue. Tissue block will be returned at completion of testing. Ship at room temperature.
NOTE: If germline MMR testing was performed in a different laboratory, a peripheral blood sample should be submitted in addition to tumor tissue.
Germline control sample:
BLOOD:
- 10 mL whole blood in LAVENDER TOP EDTA tube.
- Also acceptable: YELLOW TOP ACD tube, purified DNA from peripheral blood or cultured cells.
SALIVA:
Contact laboratory for validated collection kit.SKIN BIOPSY:
- Collection and transport: Obtain 2-4 mm punch biopsy of skin sample under sterile conditions and place in transport media (e.g. Alpha-MEM media, RPMI). Transport media can be supplied by the lab; call 206-598-4488 to request. If transport media is not available, the following media are acceptable alternatives if shipping time will not exceed 24 hours: lactated Ringer's solution, viral transport medium, or sterile saline. DO NOT USE formaldehyde, formalin, alcohol, or 5% dextrose, or tissue culture medium buffered with bicarbonate.
CULTURED CELLS:
- (2) T23 or (1) T75 flask (minimum 1-T25 flask).
- Forms & Requisitions
Requisition Form and Ordering Instructions
1. Fill out a Genetics Requisition Form
Providers with access to the UW implementation of Epic (i.e., FHCC, HMC, SCCA, UWMC, UWNW) may order this test using the order "UW Genetics and Solid Tumor Test Request." See tip sheet for more information (internal link).
2. Check "ColoSeq™ - Tumor Single Gene".
3. Specify gene in space provided.
4. Unless prior germline testing was performed at University of Washington, also select: "Normal Control (blood)".
5. Select the appropriate “Specimen Submitted".
6. Submit test requisition with peripheral blood sample and a copy of the tumor pathology report.
NOTE: Tumor specimen will be requested directly, by UW Laboratory Medicine, from the originating pathology department, and therefore, in most cases, it is not necessary to submit tumor block or slides.
- Handling Instructions
Attach a copy of the pathology report for the tumor sample being submitted.
Ship specimen at room temperature for overnight delivery.
Blood specimens can be held for up to 7 days before shipping if refrigerated.
Ship specimens to:
UW MEDICAL CENTER
LABORATORY MEDICINE - GENETICS LAB
1959 NE PACIFIC ST, ROOM NW220
SEATTLE, WA 98195-7110
- Quantity
-
requested: Entire sample
minimum: Tissue: 20 unstained slides plus one H&E-stained; slide or extracted DNA: 5 microgram AND 5 mL control peripheral blood (DNAPRP)
Processing
- Processing
Blood: Refrigerate whole blood
Unacceptable Conditions: Frozen or clotted specimens
Stability (collection to initiation of testing): Ambient: 5 days; Refrigerated: 7 days; Frozen: Unacceptable
Purified DNA: Refrigerate DNA specimens. Frozen is acceptable.
Performance
- LIS Dept Code
- Genetics (GEN)
- Performing Location(s)
-
UW-MT Genetics Attention: Genetics Lab
Clinical lab, Room NW220
University of Washington Medical Center
1959 NE Pacific Street
Seattle, WA 98195Tel: 206-598–6429 M–F (7:30 AM–4:00 PM)
Fax: 206-616-4584
Lab email: cgateam@uw.eduTel (EXOME only): 206-543-0459
Faculty
Jillian Buchan, PhD, FACMG
Runjun Kumar, MD, PhD
Regina Kwon, MD, MPH
Christina Lockwood, PhD, DABCC, DABMGG
Abbye McEwen, MD, PhD
Colin Pritchard, MD, PhD
Vera Paulson, MD, PhD
Eric Konnick, MD, MS
He Fang, PhD - Frequency
- Results within 4-6 weeks, once sample arrives in the laboratory.
- Available STAT?
- No
Billing & Coding
- CPT codes
- Billing Comments
For additional test/billing information, see ColoSeq™ Tumor Single Gene CPT codes.
For pricing information, contact Client Support Services 206-520-4600 or 800-713-5198.
Billing and Insurance Pre-Authorization
We offer insurance pre-authorization services (preauthorization is only done for providers who are external to the UW system).
Email: gpab@uw.edu or call 1-855-320-4869 for more information.
A letter of medical necessity is highly recommended for ColoSeq™ Tumor testing, and a template is available by emailing genelab@uw.edu.
- LOINC
- 51967-8
- Interfaced Order Code
- UOW2941